400 related articles for article (PubMed ID: 27461062)
1. Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.
Evangelisti C; Evangelisti C; Buontempo F; Lonetti A; Orsini E; Chiarini F; Barata JT; Pyne S; Pyne NJ; Martelli AM
Leukemia; 2016 Nov; 30(11):2142-2151. PubMed ID: 27461062
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic properties of sphingosine kinases in haematological malignancies.
Wallington-Beddoe CT; Bradstock KF; Bendall LJ
Br J Haematol; 2013 Jun; 161(5):623-638. PubMed ID: 23521541
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
Selvam SP; Ogretmen B
Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
[TBL] [Abstract][Full Text] [Related]
4. Targeting sphingosine-1-phosphate in hematologic malignancies.
Stevenson CE; Takabe K; Nagahashi M; Milstien S; Spiegel S
Anticancer Agents Med Chem; 2011 Nov; 11(9):794-8. PubMed ID: 21707492
[TBL] [Abstract][Full Text] [Related]
5. Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments.
Magli E; Corvino A; Fiorino F; Frecentese F; Perissutti E; Saccone I; Santagada V; Caliendo G; Severino B
Curr Pharm Des; 2019; 25(9):956-968. PubMed ID: 30947653
[TBL] [Abstract][Full Text] [Related]
6. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
7. The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy.
Zheng X; Li W; Ren L; Liu J; Pang X; Chen X; Kang D; Wang J; Du G
Pharmacol Ther; 2019 Mar; 195():85-99. PubMed ID: 30347210
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase inhibitors: A patent review.
Cao M; Ji C; Zhou Y; Huang W; Ni W; Tong X; Wei JF
Int J Mol Med; 2018 May; 41(5):2450-2460. PubMed ID: 29484372
[TBL] [Abstract][Full Text] [Related]
9. Drugging sphingosine kinases.
Santos WL; Lynch KR
ACS Chem Biol; 2015 Jan; 10(1):225-33. PubMed ID: 25384187
[TBL] [Abstract][Full Text] [Related]
10. Building a better sphingosine kinase-1 inhibitor.
Lynch KR
Biochem J; 2012 May; 444(1):e1-2. PubMed ID: 22533672
[TBL] [Abstract][Full Text] [Related]
11. Targeting SphK1 as a new strategy against cancer.
Shida D; Takabe K; Kapitonov D; Milstien S; Spiegel S
Curr Drug Targets; 2008 Aug; 9(8):662-73. PubMed ID: 18691013
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate.
Kharel Y; Raje M; Gao M; Gellett AM; Tomsig JL; Lynch KR; Santos WL
Biochem J; 2012 Oct; 447(1):149-57. PubMed ID: 22747486
[TBL] [Abstract][Full Text] [Related]
13. Regulation of sphingosine kinase in hematological malignancies and other cancers.
Pitson SM; Powell JA; Bonder CS
Anticancer Agents Med Chem; 2011 Nov; 11(9):799-809. PubMed ID: 21707491
[TBL] [Abstract][Full Text] [Related]
14. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.
Kennedy AJ; Mathews TP; Kharel Y; Field SD; Moyer ML; East JE; Houck JD; Lynch KR; Macdonald TL
J Med Chem; 2011 May; 54(10):3524-48. PubMed ID: 21495716
[TBL] [Abstract][Full Text] [Related]
15. Different Roles of Sphingosine Kinase 1 and 2 in Pancreatic Cancer Progression.
Yuza K; Nakajima M; Nagahashi M; Tsuchida J; Hirose Y; Miura K; Tajima Y; Abe M; Sakimura K; Takabe K; Wakai T
J Surg Res; 2018 Dec; 232():186-194. PubMed ID: 30463717
[TBL] [Abstract][Full Text] [Related]
16. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling.
Edmonds Y; Milstien S; Spiegel S
Pharmacol Ther; 2011 Dec; 132(3):352-60. PubMed ID: 21906625
[TBL] [Abstract][Full Text] [Related]
17. [Sphingosine kinase 1 and tumor].
Zhang CX; He HW; Shao RG
Yao Xue Xue Bao; 2013 Jul; 48(7):971-8. PubMed ID: 24133963
[TBL] [Abstract][Full Text] [Related]
18. Regulation and functional roles of sphingosine kinases.
Alemany R; van Koppen CJ; Danneberg K; Ter Braak M; Meyer Zu Heringdorf D
Naunyn Schmiedebergs Arch Pharmacol; 2007 Feb; 374(5-6):413-28. PubMed ID: 17242884
[TBL] [Abstract][Full Text] [Related]
19. Rational design of SphK inhibitors using crystal structures aided by computer.
Ding T; Zhi Y; Xie W; Yao Q; Liu B
Eur J Med Chem; 2021 Mar; 213():113164. PubMed ID: 33454547
[TBL] [Abstract][Full Text] [Related]
20. The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension.
Chen J; Tang H; Sysol JR; Moreno-Vinasco L; Shioura KM; Chen T; Gorshkova I; Wang L; Huang LS; Usatyuk PV; Sammani S; Zhou G; Raj JU; Garcia JG; Berdyshev E; Yuan JX; Natarajan V; Machado RF
Am J Respir Crit Care Med; 2014 Nov; 190(9):1032-43. PubMed ID: 25180446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
